455 related articles for article (PubMed ID: 21198671)
21. Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase.
Schmidt R; Holznagel E; Neumann B; Alex N; Sawatsky B; Enkirch T; Pfeffermann K; Kruip C; von Messling V; Wagner R
Vaccine; 2016 Oct; 34(44):5329-5335. PubMed ID: 27616472
[TBL] [Abstract][Full Text] [Related]
22. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
23. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.
Sambhara V
J Infect Dis; 2011 Jun; 203(11):1697-8. PubMed ID: 21593002
[No Abstract] [Full Text] [Related]
24. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.
Girard MP; Katz J; Pervikov Y; Palkonyay L; Kieny MP
Vaccine; 2010 Oct; 28(42):6811-20. PubMed ID: 20659520
[TBL] [Abstract][Full Text] [Related]
25. [Immunity against influenza virus infection].
Takada A
Nihon Rinsho; 2010 Sep; 68(9):1625-30. PubMed ID: 20845738
[TBL] [Abstract][Full Text] [Related]
26. Studies on the usefulness of intranasal inactivated influenza vaccines.
Tamura S
Vaccine; 2010 Aug; 28(38):6393-7. PubMed ID: 20493820
[TBL] [Abstract][Full Text] [Related]
27. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
28. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
[TBL] [Abstract][Full Text] [Related]
30. Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase.
Pavlova SP; Veits J; Keil GM; Mettenleiter TC; Fuchs W
Vaccine; 2009 Jan; 27(5):773-85. PubMed ID: 19041677
[TBL] [Abstract][Full Text] [Related]
31. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
[TBL] [Abstract][Full Text] [Related]
32. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
Tamura S; Tanimoto T; Kurata T
Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
[TBL] [Abstract][Full Text] [Related]
34. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants.
Keitel WA; Atmar RL; Nino D; Cate TR; Couch RB
J Infect Dis; 2008 Oct; 198(7):1016-8. PubMed ID: 18729777
[TBL] [Abstract][Full Text] [Related]
35. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
Ni Y; Guo J; Turner D; Tizard I
Front Immunol; 2018; 9():1815. PubMed ID: 30140267
[TBL] [Abstract][Full Text] [Related]
36. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
37. Emulsion-based adjuvants for influenza vaccines.
Vogel FR; Caillet C; Kusters IC; Haensler J
Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
[TBL] [Abstract][Full Text] [Related]
38. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
[TBL] [Abstract][Full Text] [Related]
39. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R
Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.
Wang W; Chen Q; Ford-Siltz LA; Katzelnick LC; Parra GI; Song HS; Vassell R; Weiss CD
Clin Infect Dis; 2019 May; 68(12):2067-2078. PubMed ID: 30256912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
